Cord blood immune cells take aim at hidden colon cancer
NCT ID NCT05040568
First seen Jan 28, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This early-phase study tested whether giving specially activated cord blood natural killer (CB-NK) cells along with the drug cetuximab could clear minimal residual disease (MRD) in 15 colon cancer patients who had completed standard treatment but still had cancer DNA in their blood. The goal was to see if this combination could eliminate remaining cancer cells that standard scans can't detect. The study focused on safety and signs of activity, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.